Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014, 158(3):428-432 | 10.5507/bp.2013.022
Aims: A retrospective analysis of patients with Hodgkin lymphoma (HL) was performed to assess their outcome regarding relative dose intensity (RDI) of chemotherapy administered in primary treatment.
Methods: A total of 194 patients were divided into three groups with different RDI of primary chemotherapy (100%, 90-99% and < 90%). Reduced RDI in two groups (90-99% and < 90%) was caused by the delay of the interval between the administration of some chemotherapeutic courses. The probability of complete remission (CR), disease relapse, event-free survival (EFS) and overall survival (OS) as the basic parameters of patient outcome were statistically compared.
Results: Multivariate analysis showed here were no significant differences in probability of CR (HR 0.9, 95% CI [0.75-1.08], P=0.5), risk of relapse (HR 1.34, 95% CI [0.92-1.94], P=0.11) or death (HR 1.52, 95% CI [0.94-2.5], P=0.13). There were also no significant differences in probability of EFS (mean 13 vs. 10 vs. 12 years, P=0.17; HR 1.54, 95% CI [0.91-2.6], P=0.22) or OS (mean 15 vs. 13 vs. 14 years, P=0.13; HR 1.52, 95% CI [0.93-2.5], P=0.13).
Conclusion: We found no significant impact of primary chemotherapy delay resulting in reduced RDI on outcome in HL patients.
Received: April 24, 2012; Accepted: March 20, 2013; Prepublished online: April 10, 2013; Published: September 30, 2014